Project Grant F31CA294913
- This federal Project Grant award, valued at $701,876.00, was provided by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) to Weill Medical College of Cornell University. The award supports a systems-level approach to therapeutically targeting the STING protein in cancer. The project aims to develop a novel technology called SATseq that couples saturation mutagenesis with single-cell sequencing to map the structure-function landscape of the STING protein,...
- This Project Grant award, totaling $102,984, was provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) to support research conducted by The Trustees of Columbia University in the City of New York. The research aims to dissect the novel role of Focal Adhesion Kinase (FAK) in modulating immunity during metastatic reactivation and progression of cancer. The key objectives are to investigate how FAK suppresses the STING innate immunity pathway, thereby enabling immune...
- This federal Project Grant award of $499,238 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at Yale University focused on enhancing the effects of DNA-damaging cancer therapies through modulation of the STING (Stimulator of Interferon Genes) pathway. The key goals are to develop a novel tumor-targeted STING agonist formulation, test its synergistic effects with DNA-damaging treatments in a STING-dependent manner, and identify the immunological...
- This $292,028 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the mechanisms by which oncogene amplification leads to genome instability and the development of therapy-resistant cancer clones. The research will be conducted by the Sloan-Kettering Institute for Cancer Research in New York and is scheduled to run from August 1, 2025 to July 31, 2030. Using single-cell genomic sequencing techniques, the project aims...
- This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $164,500 to The Trustees of Columbia University in the City of New York to investigate the mechanisms by which the protein S100A9 mediates brain metastasis in epidermal growth factor receptor (EGFR)-mutant lung cancer. The key goals are to: Examine how S100A9 expression is epigenetically regulated by histone methylation and the MEIS1 transcription factor in brain metastasis-prone cells....
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $315,246 to New York University School of Medicine to conduct research on breaking cytokine loops in lung adenocarcinoma, the leading subtype of lung cancer. The research aims to define how lung adenocarcinoma tumors with LKB1 mutations interact with the tumor microenvironment, including two specific cytokine signaling loops that promote tumor dedifferentiation and recruit...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $487,468 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct research on the role of protein palmitoylation in the progression of melanoma lung metastasis. The key objectives of the research project are to: Investigate how the palmitoyl transferase ZDHHC13 suppresses melanoma metastasis by stabilizing E-cadherin through palmitoylation...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $646,739.00 in funding to Cedars-Sinai Medical Center to investigate the molecular mechanisms underlying the role of hepatic stellate cells (HSCs) in promoting liver metastasis, particularly in the context of metabolic dysfunction-associated steatotic liver disease (MASLD). The key research objectives are to: 1) examine the regulatory mechanism and functional role of extra-tumoral...
- This $113,937 federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to the Regents of the University of Minnesota, Office of Sponsored Projects Administration, is funding research to identify methods for harnessing the potential of "bystander" T cells to develop new cancer immunotherapies. The project aims to explore how bystander T cells, which are not specific to tumor antigens, can be activated within the tumor microenvironment to...
DECODING ADAPTIVE FUNCTIONS OF STING IN CANCER PROGRESSION - PROJECT SUMMARY CANCER METASTASIS IS A COMPLEX, MULTISTEP PROCESS THAT REQUIRES CELLS TO ADAPT AND SURVIVE IN STRESSFUL CONDITIONS. THESE ADAPTIVE RESPONSES ARE CARRIED OUT BY PROTEINS WITHIN THE CELL. MANY PROTEINS CAN PLAY DIFFERENT ROLES BASED ON THEIR CONTEXT, AS HAS BEEN DEMONSTRATED FOR STIMULATOR OF INTERFERON GENES (STING). STING HAS A WELL CHARACTERIZED ROLE IN INNATE IMMUNITY AND HAS BEEN PROPOSED TO ACTIVATE AN ANTI-TUMOR IMMUNE RESPONSE EARLY IN DISEASE PROGRESSION. HOWEVER, RECENT WORK SHOWS THAT ITS CHRONIC ACTIVATION IN CANCER CELLS CAN DRIVE METASTASIS. IN ADDITION TO ITS ROLE IN THE TYPE 1 INTERFERON RESPONSE, STING ALSO HAS PUTATIVE ROLES IN ER STRESS RESPONSE SIGNALING AND THE NF-KB PATHWAY. AN EXPLANATION FOR HOW STING PLAYS THESE ROLES IS PLEIOTROPY, MEANING ONE GENE CAN CAUSE MULTIPLE, UNRELATED PHENOTYPES. IT IS UNCLEAR HOW THESE ROLES ARE MEDIATED AND HOW THESE ROLES CHANGE IN DIFFERENT CONTEXTS SUCH AS DURING CANCER PROGRESSION. MY CENTRAL HYPOTHESIS IS THAT STING ADOPTS ADAPTIVE FUNCTIONS MEDIATED THROUGH BINDING PARTNERS THAT INTERACT WITH DISTINCT FUNCTIONAL DOMAINS. THE 2 SPECIFIC AIMS OF MY PROJECT ARE (1) TO MAP THE EMERGENT DOWNSTREAM FUNCTIONS OF STING AND DETERMINE IF THESE ARE MEDIATED BY BINDING PARTNERS, AND (2) PROBE ONE PRO-METASTATIC STING VARIANT (K337X) TO UNDERSTAND HOW BINDING PARTNERS THAT STABILIZE OR DEGRADE STING INFLUENCE ITS FUNCTION. TO QUANTIFY RESIDUE-SPECIFIC FUNCTIONS OF STING IN A HIGH-THROUGHPUT MANNER, MY LAB HAS GENERATED A SATURATION MUTAGENESIS LIBRARY OF STING WITH EACH VARIANT DISTINGUISHED BY A DNA ENCODED BARCODED. WE HAVE PERFORMED SCRNA-SEQ SCREENS ON THE VARIANT LIBRARY WITH THE NATURAL AGONIST OF STING (CGAMP) TO QUANTIFY DOWNSTREAM TRANSCRIPTIONAL EFFECTS WITH EACH VARIANT. I AM NOW COUPLING SELECT VARIANTS IDENTIFIED IN THE SCREEN WITH FUNCTIONAL FLUORESCENT REPORTERS TO CLASSIFY AND VALIDATE VARIANTS ABLE TO PERFORM DOWNSTREAM INTERFERON, ER STRESS, AND NF- KB FUNCTIONS. I WILL THEN USE PROTEOMICS TO IDENTIFY IF BINDING PARTNERS ARE RESPONSIBLE FOR DIFFERENCES IN VARIANT FUNCTION. WE HAVE ALSO PERFORMED 2 METASTASIS ASSAY SCREENS WITH THE LIBRARY AND IDENTIFIED ONE STRIKING PRO- METASTATIC VARIANT, K337X. I AM FOLLOWING UP ON 2 SPECIFIC BINDING PARTNERS THAT ARE KNOWN TO EITHER STABILIZE OR PROMOTE DEGRADATION OF STING TO TEST IF THE CONTEXT OF STING, MEANING BINDING PARTNERS AVAILABLE, RATHER THAN SPECIFIC CLINICAL MUTATIONS COULD BE RESPONSIBLE FOR ITS EMERGENT FUNCTIONS. I WILL STUDY THESE FUNCTIONS OF STING IN 2 MOUSE MODELS OF CHROMOSOMALLY UNSTABLE TRIPLE NEGATIVE BREAST CANCER CELL LINES. THE LONG-TERM GOAL OF THIS WORK IS TO BETTER UNDERSTAND THE MEDIATORS OF STING'S FUNCTIONS SO THAT ITS DYSREGULATION IN CANCER CAN BE BETTER UNDERSTOOD AND MORE EFFECTIVELY TARGETED WITH THERAPEUTICS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $49.5k | 7/14/25 | ||
| Not listed | $49.5k | 7/14/25 | ||
| Not listed | $0 | 7/14/25 |